Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574181 · ClinicalTrials.gov registry record
Calibration Study of a Blood Alcohol Level Smart Watch
A clinical trial, sponsored by Boston Medical Center.
- Terminated
- Registry status
- 9
- Enrollment target
NCT03574181: Clinical Trial study, sponsored by Boston Medical Center.
NCT03574181 is a clinical trial that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03574181 was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- 9 participants
- Enrollment target
Study Summary
This trial is designed to test the accuracy of a wristwatch blood alcohol level monitor relative to alcohol breath testing. An established human laboratory self-administration procedure will be followed. Each subject will complete 2 clinic visits over a period of up to 21 days of participation. Study participation is comprised of a baseline assessment to determine eligibility and an alcohol self-administration trial to test the accuracy of the wrist watch blood alcohol level. Subjects will be recruited in two phases of 9 subjects each. The first phase will be conducted to validate a prototype of the wrist watch. The second phase will be conducted to validate a pre-production consumer model of the blood alcohol wrist watch.
Primary Outcome
Wristwatch sensor BAL is continuously measured for entirety of 6-hour alcohol self administration trial. BAL from breathalyzer (BrAC) is measured at 15-minute intervals throughout 6-hour alcohol self administration trial. The correlation between wristwatch transdermal BAL (TAC) and breathalyzer BAL (BrAC) for all subjects will be calculated.
Interventions
- OTHER Smartwatch to measure Blood Alcohol Level (BAL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2020-02-17 |
Why NCT03574181 stopped before completion
NCT03574181 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Smartwatch to measure Blood Alcohol Level (BAL) is the first listed.
NCT03574181 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03574181 about?
NCT03574181 is a clinical study titled "Calibration Study of a Blood Alcohol Level Smart Watch". This trial is designed to test the accuracy of a wristwatch blood alcohol level monitor relative to alcohol breath testing. An established human laboratory self-administration procedure will be followed. Each subject will complete 2 clinic visits over a period of up to 21 days of participation. Stud...
What is the current status of trial NCT03574181?
This trial is currently terminated. The enrollment target is 9 participants. The study started on 2019-07-08. Estimated completion is 2020-02-17.
What interventions are being tested in trial NCT03574181?
The interventions under investigation include: Smartwatch to measure Blood Alcohol Level (BAL) (OTHER).
Who is sponsoring clinical trial NCT03574181?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI